

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed

<https://marketpublishers.com/r/T0D7362350DEN.html>

Date: July 2013

Pages: 14

Price: US\$ 800.00 (Single User License)

ID: T0D7362350DEN

Abstracts

TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up!

In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed a paradigm shift due to the launch of various new drugs (Jevtana, Zytiga, Xtandi, Provenge). There are also a number of new candidates in late stage development to hit this market through different pathways. In the pipeline (Table 2), ~4 drugs are in late stage clinical development to compete against both these molecules (TAK-700, TOK-001, ODM-021, ARN-509), in which TAK-700 is the most advanced. TAK-700 is a selective inhibitor of 17, 20 lyase for production of steroidal hormone (Chart 1). By mechanism of action, it is a more specific 17, 20 lyase inhibitor. Though there is a high chance that Zytiga patent will get extension beyond 2020, TAK-700 profile. TAK-700 will be the treatment of choice in patients who.. Phase III data of TAK-700 in mCRPC patients is due in 2H 2013. Table 3 highlights the expected key events which have the potential to change the current treatment paradigm of prostate cancer.

TAK-700 vs. Approved anti Androgen therapy (Table 5, 6): How is TAK-700 different from Zytiga (Table 1) in its mechanism of Action? Has this differentiation been revealed in reported clinical trial data?

Tables Included:

Table 1: Comparison of CYP17 Inhibitors Pipeline Drugs Acting On Androgen Synthesis

Table 2: Key Candidates Of Anti Androgen Therapy In Prostate Cancer

Table 3: Upcoming Milestones- TAK-700

Table 4: Reported Clinical Data of TAK-700

Table 5 Clinical Data Comparision- TAK-700 vs. Zytiga vs. TOK-001

Table 6: Clinical Data Comparision- TAK- 700 vs. Xtandi vs. ARN-509 vs ODM-201

Table 7: Prostate cancer –Market dynamics year 2016 and beyond

Table 8: TAK-700- Ongoing Clinical trials

I would like to order

Product name: TAK-700 - No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed

Product link: <https://marketpublishers.com/r/T0D7362350DEN.html>

Price: US\$ 800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T0D7362350DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970